Forest has well-established franchises in the therapeutic areas of the central nervous and cardiovascular systems, and we are always exploring new product opportunities that address a range of health conditions. Our principal brands include Bystolic® (nebivolol), Daliresp™ (roflumilast), Lexapro® (escitalopram oxalate), Namenda® (memantine HCl), Savella®(milnacipran HCl), Teflaro® (ceftaroline fosamil) for injection, and Viibryd™ (vilazodone HCl). Forest identifies, develops, and delivers pharmaceutical products that make a difference in people\’s lives. We have been extremely successful in meeting our business objectives and expanding our franchises, but we also derive satisfaction in helping to bring relief to people who are suffering. We credit our success to our innovation, integrity, and commitment to developing important products.